Company profile
Lymphatica Medtech SA
Lymphatica is a medical device development company that has designed and patented the first implantable system for chronic lymphedema treatment, which will improve the quality of life of millions of patients in the world. Chronic lymphedema is a common side effect of cancer therapies that causes chronic swelling of the limbs, pain and recurrent infections, leading to a state of chronic disability. More than 10 million people in Europe and US have lymphedema. Lymphatica is a new hope for the patient and a new tool for healthcare specialists.
Source: startup.ch
More news about Lymphatica Medtech SA
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
